We agree completely with the assertions of Drs Goldstein and Jüni and colleagues that the 3 studies recently published in the ARCHIVES regarding naproxen and the risk of acute MI1- 3 do not provide evidence regarding the safety of the selective COX-2 inhibitors, since none of these studies contain patients taking these agents.
Solomon D, Avorn J, Glynn RJ. Risk of Myocardial Infarction Associated With Selective COX-2 Inhibitors: Questions Remain—Reply. Arch Intern Med. 2002;162(22):2640. doi: